BOAN BIOTECH (06955) Shareholder Transfers Shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong, Portfolio Value of HK$346 Million

Stock News

01/27

According to the latest data from the Hong Kong Stock Exchange, on January 26, a shareholder of BOAN BIOTECH (06955) transferred shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong. The transferred portfolio was valued at HK$346 million, representing a 6.32% stake.

BOAN BIOTECH announced that the company's board of directors has been notified by its controlling shareholder, Luye Pharma Group, that, pursuant to the terms of the subscription agreement related to exchangeable preferred shares, it plans to arrange for its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to complete a proposed transfer of an additional 11.9866 million H shares to the issuer on the market by January 27, 2026.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1123106870"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123106870\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123106870?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 08:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123106870","market":"hk","top_or_hot":-1,"title":"BOAN BIOTECH (06955) Shareholder Transfers Shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong, Portfolio Value of HK$346 Million","media":"Stock News","content":"<p>According to the latest data from the Hong Kong Stock Exchange, on January 26, a shareholder of BOAN BIOTECH (06955) transferred shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong. The transferred portfolio was valued at HK$346 million, representing a 6.32% stake.</p>\n<p>BOAN BIOTECH announced that the company's board of directors has been notified by its controlling shareholder, Luye Pharma Group, that, pursuant to the terms of the subscription agreement related to exchangeable preferred shares, it plans to arrange for its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to complete a proposed transfer of an additional 11.9866 million H shares to the issuer on the market by January 27, 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BOAN BIOTECH (06955) Shareholder Transfers Shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong, Portfolio Value of HK$346 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBOAN BIOTECH (06955) Shareholder Transfers Shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong, Portfolio Value of HK$346 Million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-01-27 08:56</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>According to the latest data from the Hong Kong Stock Exchange, on January 26, a shareholder of BOAN BIOTECH (06955) transferred shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong. The transferred portfolio was valued at HK$346 million, representing a 6.32% stake.</p>\n<p>BOAN BIOTECH announced that the company's board of directors has been notified by its controlling shareholder, Luye Pharma Group, that, pursuant to the terms of the subscription agreement related to exchangeable preferred shares, it plans to arrange for its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to complete a proposed transfer of an additional 11.9866 million H shares to the issuer on the market by January 27, 2026.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0276","symbol_name":"資本市場","start_time":0,"source_url":"","article_id":"1123106870","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123106870","pubTimestamp":1769475381,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to the latest data from the Hong Kong Stock Exchange, on January 26, a shareholder of BOAN BIOTECH (06955) transferred shares from China Securities Depository and Clearing Hong Kong to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161027":"证券","600030":"中信证券","BK0276":"资本市场","06030":"中信证券","BK1161":"生物科技","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK1516":"腾讯概念","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK1147":"投资银行业与经纪业","BK0196":"行业龙头","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK1521":"挪威政府全球养老基金持仓","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","06955":"博安生物","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","BK0183":"MSCI概念","LU1720050803.USD":"安联全方位中国股票基金","BK0188":"融资融券","BK0012":"证金概念","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK1564":"中资券商股","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","BK0028":"国家队"},"translate_title":"博安生物(06955)股东从中国证券登记结算香港转让股份至中信证券经纪香港，组合价值3.46亿港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1,"600030":1,"06955":1,"06030":1},"content_text":"According to the latest data from the Hong Kong Stock Exchange, on January 26, a shareholder of BOAN BIOTECH (06955) transferred shares from China Securities Depository and Clearing Hong Kong to CITIC SEC Brokerage Hong Kong. The transferred portfolio was valued at HK$346 million, representing a 6.32% stake.\nBOAN BIOTECH announced that the company's board of directors has been notified by its controlling shareholder, Luye Pharma Group, that, pursuant to the terms of the subscription agreement related to exchangeable preferred shares, it plans to arrange for its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to complete a proposed transfer of an additional 11.9866 million H shares to the issuer on the market by January 27, 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}